Screener
Protagonist Therapeutics PTGX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $420,078 | $128,390 |
| Marketable securities | 362,498 | 438,974 |
| Receivable from collaboration partner | 13,416 | 121 |
| Contract asset | 3,366 | — |
| Prepaid expenses and other current assets | 7,790 | 10,089 |
| Total current assets | 807,148 | 577,574 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's short-term investments?
- Protagonist Therapeutics (PTGX) reported short-term investments of $362.5M in Q2 2026.
- How has Protagonist Therapeutics's short-term investments changed year-over-year?
- Protagonist Therapeutics's short-term investments decreased by 9.8% year-over-year, from $401.92M to $362.5M.
- What is the long-term trend for Protagonist Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's short-term investments has grown at a 18.4% compound annual growth rate (CAGR), from $188.45M to $438.97M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Protagonist Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude